School of Medicine
Peter Mullen has not added Biography.
If you are Peter Mullen and would like to personalize this page please email our Author Liaison for assistance.
PARP cleavage as a means of assessing apoptosis.
Methods in molecular medicine , 2004 | Pubmed ID: 14634228
Flow cytometric DNA analysis of human cancer cell lines.
Methods in molecular medicine , 2004 | Pubmed ID: 14634236
The use of Matrigel to facilitate the establishment of human cancer cell lines as xenografts.
Methods in molecular medicine , 2004 | Pubmed ID: 14634240
Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2004 | Pubmed ID: 15041731
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Cancer research Aug, 2005 | Pubmed ID: 16061661
Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.
International journal of cancer. Journal international du cancer Mar, 2006 | Pubmed ID: 16184551
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.
Carcinogenesis Apr, 2006 | Pubmed ID: 16332724
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.
Molecular cancer therapeutics Jan, 2007 | Pubmed ID: 17237269
Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo.
Cancer research Aug, 2008 | Pubmed ID: 18676858
Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.
Cancer research Aug, 2009 | Pubmed ID: 19638581
Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Molecular cancer research : MCR Sep, 2009 | Pubmed ID: 19737968
Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy.
Biochemical pharmacology Apr, 2010 | Pubmed ID: 20018177
Serotonin, a catecholamine?
Headache Apr, 2010 | Pubmed ID: 20100295
Pertuzumab for the treatment of ovarian cancer.
Expert opinion on biological therapy Jul, 2010 | Pubmed ID: 20465533
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Cancer research Nov, 2010 | Pubmed ID: 20861192
Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.
European journal of cancer (Oxford, England : 1990) Jun, 2011 | Pubmed ID: 21334202
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2011 | Pubmed ID: 21571868
Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt.
Biochimica et biophysica acta Dec, 2011 | Pubmed ID: 21839782
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.
PloS one , 2011 | Pubmed ID: 21909357
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Cellular signalling Feb, 2012 | Pubmed ID: 21996585
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences Nov, 2011 | Pubmed ID: 22085636
Diversity of matriptase expression level and function in breast cancer.
PloS one , 2012 | Pubmed ID: 22514623
Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines.
Bioorganic & medicinal chemistry letters Jul, 2012 | Pubmed ID: 22721713
Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans.
Therapeutic drug monitoring Aug, 2012 | Pubmed ID: 22743351
New strategies for targeting the hypoxic tumour microenvironment in breast cancer.
Cancer treatment reviews Apr, 2013 | Pubmed ID: 23063837
Fiach C. O'Mahony1,
Jyoti Nanda1,
Alexander Laird1,
Peter Mullen2,
Helen Caldwell3,
Ian M. Overton4,
Lel Eory4,
Marie O'Donnell1,5,
Dana Faratian6,
Thomas Powles7,
David J. Harrison1,2,
Grant D. Stewart1
1Edinburgh Urological Cancer Group, University of Edinburgh,
2School of Medicine, University of St Andrews,
3Division of Pathology, University of Edinburgh,
4MRC Human Genetics Unit, MRC IGMM, University of Edinburgh,
5Department of Pathology, Western General Hospital,
6Breakthrough Breast Cancer Research Unit, University of Edinburgh,
7St Bartholomew's Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados